Recombinant Human Hyaluronidase-Facilitated Subcutaneous Immunoglobulin Infusion in Primary Immunodeficiency Diseases

AGAMMAGLOBULINEMIA

BRUTON, O. C. (1952) · Pediatrics · doi:10.1542/peds.9.6.722 · Cited by 1,492 · see citing works

Update on the use of immunoglobulin in human disease: A review of evidence

Pérez, E., Orange, J. S., Bonilla, F. A., Chinen, J., Chinn, I. K., Dorsey, M. J., El‐Gamal, Y., Harville, T., Hossny, E. M., Mazer, B. D., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 668 · see citing works

Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies

Orange, J. S., Grossman, W. J., Navickis, R. J., & Wilkes, M. M. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.06.012 · Cited by 435 · see citing works

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

Baker, M., Reynolds, H. M., Lumicisi, B., & Bryson, C. J. (2010) · Self/Nonself · doi:10.4161/self.1.4.13904 · Cited by 372 · see citing works

Primary Immunodeficiency Diseases Worldwide: More Common than Generally Thought

Bousfiha, A. A., Jeddane, L., Ailal, F., Benhsaien, I., Mahlaoui, N., Casanova, J., & Abel, L. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9751-7 · Cited by 323 · see citing works

Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration

Frost, G. I. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.427 · Cited by 323 · see citing works

Enzymatic Depletion of Tumor Hyaluronan Induces Antitumor Responses in Preclinical Animal Models

Thompson, C. B., Shepard, H. M., O'Connor, P. M., Kadhim, S., Jiang, P., Osgood, R. J., Bookbinder, L. H., Li, X., Sugarman, B. J., Connor, R. J., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0470 · Cited by 298 · see citing works

The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies

Bousfiha, A. A., Jeddane, L., Al–Herz, W., Ailal, F., Casanova, J., Chatila, T. A., Conley, M. E., Cunningham‐Rundles, C., Etzioni, A., Franco, J. L., et al. (2015) · Journal of Clinical Immunology · doi:10.1007/s10875-015-0198-5 · Cited by 297 · see citing works

HIGH-DOSE VERSUS LOW-DOSE INTRAVENOUS IMMUNOGLOBULIN IN HYPOGAMMAGLOBULINAEMIA AND CHRONIC LUNG DISEASE

Roifman, C. M., Levison, H., & Gelfand, E. W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)90494-6 · Cited by 292 · see citing works

A recombinant human enzyme for enhanced interstitial transport of therapeutics

Bookbinder, L. H., Hofer, A., Haller, M. F., Zepeda, M. L., Keller, G.-A., Lim, J. E., Edgington, T. S., Shepard, H. M., Patton, J. S., & Frost, G. I. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.027 · Cited by 282 · see citing works

Mouse Sperm Lacking Cell Surface Hyaluronidase PH-20 Can Pass through the Layer of Cumulus Cells and Fertilize the Egg

Baba, D., Kashiwabara, S., Honda, A., Yamagata, K., Wu, Q., Ikawa, M., Okabe, M., & Baba, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204596200 · Cited by 185 · see citing works

Biologic IgG level in primary immunodeficiency disease: The IgG level that protects against recurrent infection

Bonagura, V. R., Marchlewski, R. J., Cox, A. L., & Rosenthal, D. W. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.04.044 · Cited by 168 · see citing works

THE EFFECT OF EXTRACTS OF CERTAIN ORGANS FROM NORMAL AND IMMUNIZED ANIMALS ON THE INFECTING POWER OF VACCINE VIRUS

Duran‐Reynals, F. (1929) · The Journal of Experimental Medicine · doi:10.1084/jem.50.3.327 · Cited by 153 · see citing works

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

Wasserman, R. L., Melamed, I., Stein, M. R., Gupta, S., Puck, J. M., Engl, W., Leibl, H., McCoy, B., Empson, V. G., Gelmont, D. M., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.021 · Cited by 151 · see citing works

cDNA cloning reveals the molecular structure of a sperm surface protein, PH-20, involved in sperm-egg adhesion and the wide distribution of its gene among mammals.

Lathrop, W. F., Carmichael, E. P., Myles, D. G., & Primakoff, P. (1990) · The Journal of Cell Biology · doi:10.1083/jcb.111.6.2939 · Cited by 147 · see citing works

Subcutaneous immunoglobulin: opportunities and outlook

Misbah, S., Sturzenegger, M., Borte, M., Shapiro, R. S., Wasserman, R. L., Berger, M., & Ochs, H. D. (2009) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2009.04027.x · Cited by 139 · see citing works

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase

Shpilberg, O., & Jackisch, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.371 · Cited by 138 · see citing works

Prevalence and Morbidity of Primary Immunodeficiency Diseases, United States 2001–2007

Kobrynski, L. J., Powell, R., & Bowen, S. M. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0102-8 · Cited by 128 · see citing works

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

Davies, A., Merli, F., Mihaljević, B., Mercadal, S., Siritanaratkul, N., Solal-Céligny, P., Boehnke, A., Berge, C., Genevray, M., Zharkov, A., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30078-9 · Cited by 125 · see citing works

Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies

Yong, P. L., Boyle, J. M., Ballow, M. C., Boyle, M. L., Berger, M., Bleesing, J., Bonilla, F. A., Chinen, J., Cunningham‐Rundles, C., Fuleihan, R., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.10.003 · Cited by 110 · see citing works

Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment, and discovery

Modell, V., Knaus, M., Modell, F., Roifman, C. M., Orange, J. S., & Notarangelo, L. D. (2014) · Immunologic Research · doi:10.1007/s12026-014-8498-z · Cited by 106 · see citing works

Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again

Wasserman, R. L. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9740-x · Cited by 92 · see citing works

Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment

Español, T., Olding, L., Prevot, J., Drabwell, J., & Sondhi, S. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s60771 · Cited by 82 · see citing works

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases

Kobrynski, L. J. (2012) · Biologics · doi:10.2147/btt.s25188 · Cited by 81 · see citing works

Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease

Wasserman, R. L., Melamed, I., Kobrynski, L. J., Strausbaugh, S. D., Stein, M. R., Sharkhawy, M., Engl, W., Leibl, H., Sobolevsky, L., Gelmont, D. M., et al. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9512-z · Cited by 76 · see citing works

Assessment and Implication of the Allergic Sensitivity to a Single Dose of Recombinant Human Hyaluronidase Injection

Yocum, R. C., Kennard, D. A., & Heiner, L. S. (2007) · Journal of Infusion Nursing · doi:10.1097/01.nan.0000292572.70387.17 · Cited by 74 · see citing works

Overview of Recombinant Human Hyaluronidase-facilitated Subcutaneous Infusion of IgG in Primary Immunodeficiencies

Wasserman, R. L. (2014) · Immunotherapy · doi:10.2217/imt.14.34 · Cited by 65 · see citing works

Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

Suez, D., Stein, M. R., Gupta, S., Hussain, I., Melamed, I., Paris, K., Darter, A., Bourgeois, C., Fritsch, S., Leibl, H., et al. (2016) · Journal of Clinical Immunology · doi:10.1007/s10875-016-0327-9 · Cited by 63 · see citing works

Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration

Rosengren, S., Dychter, S. S., Printz, M. A., Huang, L., Schiff, R. I., Schwarz, H.-P., McVey, J. K., Drake, F. H., Maneval, D. C., Kennard, D. A., et al. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9782-0 · Cited by 58 · see citing works

Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies

Borte, M., Kriván, G., Dérfalvi, B., Maródi, L., Harrer, T., Jolles, S. R. A., Bourgeois, C., Engl, W., Leibl, H., McCoy, B., et al. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12866 · Cited by 54 · see citing works

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

Wasserman, R. L., Melamed, I., Stein, M. R., Engl, W., Sharkhawy, M., Leibl, H., Puck, J., Rubinstein, A., Kobrynski, L., Gupta, S., et al. (2016) · Journal of Clinical Immunology · doi:10.1007/s10875-016-0298-x · Cited by 52 · see citing works

A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis

Shabaninejad, H., Asgharzadeh, A., Rezaei, N., & Rezapoor, A. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1155452 · Cited by 52 · see citing works

Recombinant Human Hyaluronidase Facilitated Subcutaneous Immunoglobulin Treatment in Pediatric Patients with Primary Immunodeficiencies: Long-Term Efficacy, Safety and Tolerability

Wasserman, R. L., Melamed, I., Kobrynski, L. J., Puck, J. M., Gupta, S., Doralt, J., Sharkhawy, M., Engl, W., Leibl, H., Gelmont, D. M., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0066 · Cited by 40 · see citing works

Incidence of Infection is Inversely Related to Steady-State (Trough) Serum IgG Level in Studies of Subcutaneous IgG in PIDD

Berger, M. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9546-2 · Cited by 37 · see citing works

Assessment of contraceptive vaccines based on recombinant mouse sperm protein PH20

Hardy, C. M., Clydesdale, G. J., Mobbs, K. J., Pekin, J., Lloyd, M. L., Sweet, C., SHELLAM, G. R., & Lawson, M. A. (2004) · Reproduction · doi:10.1530/rep.1.00016 · Cited by 36 · see citing works

Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer

Freyer, G., Bakrin, Hamizi, Hénin, É., Mohtaram, Saux, O. L., & Falandry, C. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s27733 · Cited by 30 · see citing works

Restricted Entry of IgG into Male and Female Rabbit Reproductive Ducts Following Immunization with Recombinant Rabbit PH‐20

Pomering, M., Jones, R. C., Holland, M. K., Blake, A. E., & Beagley, K. W. (2002) · American Journal of Reproductive Immunology · doi:10.1034/j.1600-0897.2002.1o056.x · Cited by 29 · see citing works

Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model

Kang, D. W., Jadin, L., Nekoroski, T., Drake, F. H., & Zepeda, M. L. (2012) · Drug Delivery and Translational Research · doi:10.1007/s13346-012-0065-3 · Cited by 27 · see citing works

Functional Characterization of Double-knockout Mouse Sperm Lacking SPAM1 and ACR or SPAM1 and PRSS21 in Fertilization

Zhou, C., Kang, W., & Baba, T. (2012) · Journal of Reproduction and Development · doi:10.1262/jrd.2011-006 · Cited by 24 · see citing works

Hypogammaglobulinemia: therapeutic rationale.

Long, A. A., Denburg, J., & Dent, P. B. (1987) · PubMed · Cited by 11 · see citing works

Impact of Site of Care on Infection Rates Among Patients with Primary Immunodeficiency Diseases Receiving Intravenous Immunoglobulin Therapy

Wasserman, R. L., Ito, D., Xiong, Y., Ye, X., Bonnet, P. O., & Li-McLeod, J. M. (2017) · Journal of Clinical Immunology · doi:10.1007/s10875-017-0371-0 · Cited by 10 · see citing works

The ratio of mean daily IgG increment/mean daily dose in immunoglobulin replacement therapy in primary antibody deficiencies

Lucas, M., Lee, M. W., Oksenhendler, É., & Chapel, H. M. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.07.001 · Cited by 8 · see citing works

P255 Real-world pediatric experience with hyaluronidase-facilitated subcutaneous immunoglobulin (IGHY) infusion parameters

Gruenemeier, P., Ernst, C., White, C., & Duff, K. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.09.268 · Cited by 4 · see citing works

P259 Retrospective review of needle length and clinical considerations during hyaluronidase-facilitated subcutaneous administration of immunoglobulin (IGHY)

Gruenemeier, P., Ernst, C., Palagashvili, T., & Duff, K. (2016) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2016.09.272 · Cited by 3 · see citing works

Non-invasive delivery strategies for biologics

Anselmo, A. C., Gokarn, Y. R., & Mitragotri, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.183 · Cited by 671 · see citing works

Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities

Bittner, B., Richter, W., & Schmidt, J. (2018) · BioDrugs · doi:10.1007/s40259-018-0295-0 · Cited by 447 · see citing works

Clinical Applications of Hyaluronidase

Weber, G. C., Buhren, B. A., Schrumpf, H., Wohlrab, J., & Gerber, P. A. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-7709-9_12 · Cited by 115 · see citing works

Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics

Collins, D. S., Sánchez-Félix, M., Badkar, A. V., & Mrsny, R. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.036 · Cited by 113 · see citing works

Strategies for Glycoengineering Therapeutic Proteins

Dammen-Brower, K., Epler, P., Zhu, S., Bernstein, Z. J., Stabach, P., Braddock, D., Spangler, J. B., & Yarema, K. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.863118 · Cited by 54 · see citing works

Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults

Woodley, W. D., Morel, D. R., Sutter, D. E., Pettis, R. J., & Bolick, N. G. (2021) · Clinical and Translational Science · doi:10.1111/cts.13109 · Cited by 49 · see citing works

Hyaluronidase-powered microneedles for significantly enhanced transdermal delivery efficiency

Hu, W., Peng, T., Huang, Y., Ren, T., Chen, H., Chen, Y., Feng, D., Wu, C., & Pan, X. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.046 · Cited by 50 · see citing works

Stability of Protein Pharmaceuticals: Recent Advances

Manning, M. C., Holcomb, R. E., Payne, R. W., Stillahn, J. M., Connolly, B. D., Katayama, D. S., Liu, H., Matsuura, J. E., Murphy, B. M., Henry, C. S., et al. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03726-x · Cited by 43 · see citing works

Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design

Mathias, N. R., Huille, S., Picci, M., Mahoney, R. P., Pettis, R. J., Case, B. C., Helk, B., Kang, D. W., Shah, R., Ma, J., et al. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115301 · Cited by 42 · see citing works

Hyaluronidases and hyaluronate lyases: From humans to bacteriophages

Šindelář, M., Jílková, J., Kubala, L., Velebný, V., & Turková, K. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.112095 · Cited by 39 · see citing works

Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation

Farrera-Sal, M., Moreno, R., Mato-Berciano, A., Maliandi, M. V., Bazán‐Peregrino, M., & Alemany, R. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.009 · Cited by 30 · see citing works

Modeling large-volume subcutaneous injection of monoclonal antibodies with anisotropic porohyperelastic models and data-driven tissue layer geometries

de Lucio, M., Leng, Y., Hans, A., Bilionis, I., Brindise, M. C., Ardekani, A. M., Vlachos, P. P., & Gómez, H. (2022) · Journal of the mechanical behavior of biomedical materials/Journal of mechanical behavior of biomedical materials · doi:10.1016/j.jmbbm.2022.105602 · Cited by 30 · see citing works

Hyaluronidase overcomes the extracellular matrix barrier to enhance local drug delivery

Zhao, J., Chen, J., Li, C., Xiang, H., & Miao, X. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114474 · Cited by 28 · see citing works

Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats

Styles, I. K., Feeney, O. M., Nguyen, T., Brundel, D. H. S., Kang, D. W., Clift, R., McIntosh, M. P., & Porter, C. J. H. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.040 · Cited by 26 · see citing works

Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study

Pulvirenti, F., Cinetto, F., Pecoraro, A., Carrabba, M., Crescenzi, L., Neri, R., Bonanni, L., Fabio, G., Agostini, C., Spadaro, G., et al. (2019) · Journal of Clinical Immunology · doi:10.1007/s10875-019-0592-5 · Cited by 24 · see citing works

A clinician’s guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases

Epland, K., Suez, D., & Paris, K. (2022) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-022-00726-7 · Cited by 24 · see citing works

Dispersive effects and focused biodistribution of recombinant human hyaluronidase PH20: A locally acting and transiently active permeation enhancer

Kang, D. W., Bittner, B., Sugarman, B. J., Zepeda, M. L., & Printz, M. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254765 · Cited by 21 · see citing works

Clinical Investigation of Large Volume Subcutaneous Delivery up to 25 mL for Lean and Non-Lean Subjects

Dang, X., Shih, H., Sharma, R. K., Angwin-Kaerner, D. T., Lin, K., Kapur, S., Thyagarajapuram, N. R., Shi, G. H., & Collins, D. S. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03683-5 · Cited by 20 · see citing works

Injection site reactions of biologics and mitigation strategies

Zhi, L., Liu, D., & Shameem, M. (2025) · AAPS Open · doi:10.1186/s41120-025-00108-4 · Cited by 20 · see citing works

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study

Borte, M., Hanitsch, L. G., Mahlaoui, N., Faßhauer, M., Huscher, D., Speletas, M. G., Dimou, M., Kamieniak, M. M., Hermann, C., Pittrow, D., et al. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01470-2 · Cited by 18 · see citing works

Randomized trial of facilitated subcutaneous immunoglobulin in multifocal motor neuropathy

Al‐Zuhairy, A., Jakobsen, J. C., Andersen, H., Sindrup, S. H., & Markvardsen, L. H. (2019) · European Journal of Neurology · doi:10.1111/ene.13978 · Cited by 17 · see citing works

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

Keith, P. K., Cowan, J., Kanani, A. S., Kim, H. L., Lacuesta, G., Lee, J. K., Chen, J., Park, M., & Gladiator, A. (2022) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-022-00709-8 · Cited by 14 · see citing works

Use of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Immunoglobulin in Elderly Patients

van Paassen, P., Pittrow, D., Scheidegger, C., Klotsche, J., & Ellerbroek, P. M. (2020) · Immunotherapy · doi:10.2217/imt-2019-0175 · Cited by 13 · see citing works

Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases

Baumann, U., Faßhauer, M., Pausch, C., Wittkowski, H., Hermann, C., Pittrow, D., & Borte, M. (2021) · Immunotherapy · doi:10.2217/imt-2021-0167 · Cited by 11 · see citing works

Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies

Li, Z., Follman, K., Freshwater, E., Engler, F. A., & Yel, L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109331 · Cited by 11 · see citing works

Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis

Dimou, M., Speletas, M. G., Milito, C., Pyzik, A., Huscher, D., Kamieniak, M. M., Pittrow, D., & Borte, M. (2023) · Cancers · doi:10.3390/cancers15184524 · Cited by 10 · see citing works

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases

Li, Z., Follman, K., Freshwater, E., Engler, F. A., & Yel, L. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01572-x · Cited by 10 · see citing works

Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort

Gungoren, E. Y., Altunbaş, M. Y., Dikici, Ü., Meric, Z., Şimşek, I. E., Kıykım, A. A., Can, S., Karabıber, E., Yakıcı, N., Orhan, F., et al. (2024) · Journal of Clinical Immunology · doi:10.1007/s10875-024-01771-0 · Cited by 10 · see citing works

Development pathways for subcutaneous formulations of biologics versus biosimilar development

Zharkov, A., Barton, B., Heinzmann, D., Bakalos, G., & Schreitmüller, T. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1585806 · Cited by 10 · see citing works

Immunoglobulin therapies for primary immunodeficiency diseases (part 2): considerations for dosing strategies

Li, Z., & Mahmood, I. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2382074 · Cited by 9 · see citing works

Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics

Mahmood, I., & Li, Z. (2024) · Immunotherapy · doi:10.1080/1750743x.2024.2382081 · Cited by 9 · see citing works

Mechanistic Modeling of the Effect of Recombinant Human Hyaluronidase (rHuPH20) on Subcutaneous Delivery of Cetuximab in Rats

Gao, X., Lee, J. B., Deshpande, K., Kang, D. W., Fathallah, A. M., & Kagan, L. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03294-y · Cited by 8 · see citing works

Drug delivery improvements to enable a flexible care setting for monoclonal antibody medications in oncology - Analogue-based decision framework

Bittner, B. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2184343 · Cited by 8 · see citing works

Real-World Effectiveness, Safety, and Tolerability of Facilitated Subcutaneous Immunoglobulin 10% in Secondary Immunodeficiency Disease: A Systematic Literature Review

Dimou, M., Vacca, A., Sánchez‐Ramón, S., Karakulska‐Prystupiuk, E., Lionikaite, V., Siffel, C., Anderson‐Smits, C., & Kamieniak, M. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041203 · Cited by 7 · see citing works

Pharmaceutical Perspective in Wearable Drug Delivery Systems

Tharmatt, A., Malhotra, D., Sharma, H., & Bedi, N. (2021) · Assay and Drug Development Technologies · doi:10.1089/adt.2021.008 · Cited by 7 · see citing works

Immunoglobulin therapy for immunodeficiency

Wilson, B. E., & Freeman, C. M. (2024) · Allergy and Asthma Proceedings · doi:10.2500/aap.2024.45.240053 · Cited by 7 · see citing works

Long-term follow-up of facilitated subcutaneous immunoglobulin therapy in multifocal motor neuropathy

Al‐Zuhairy, A., Sindrup, S. H., & Jakobsen, J. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117495 · Cited by 6 · see citing works

Infection Rates and Tolerability of Three Different Immunoglobulin Administration Modalities in Patients with Primary Immunodeficiency Diseases

Wasserman, R. L., Gupta, S., Stein, M. R., Rabbat, C. J., Engl, W., Leibl, H., & Yel, L. (2021) · Immunotherapy · doi:10.2217/imt-2021-0256 · Cited by 6 · see citing works

Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies

Li, Z., Follman, K., Freshwater, E., Engler, F. A., & Yel, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111447 · Cited by 5 · see citing works

Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study

Rubinstein, A., Mabudian, M. I., McNeil, D. L., Patel, N., Wasserman, R. L., Gupta, S., Carrasco, P., Chen, J., García, E., Nagy, A., et al. (2024) · Journal of Clinical Immunology · doi:10.1007/s10875-024-01769-8 · Cited by 5 · see citing works

A comprehensive strategy for the identification of biologics by liquid-chromatography–mass spectrometry for release testing in a regulated environment

Morales, A., Candreva, J., Jayarathne, T., Esterman, A. L., Voruganti, S., Flagg, S. C., Slaney, T. R., Liu, P., Adamo, M., Patel, S., et al. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115580 · Cited by 5 · see citing works

Update on real-world use of facilitated subcutaneous immunoglobulin and immune globulin subcutaneous (human) 20% solution in patients with immunodeficiencies: poster extracts from the 19th Biennial Meeting of the European Society for Immunodeficiencies

Borte, M., Anderson‐Smits, C., & Hermann, C. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1913122 · Cited by 5 · see citing works

Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants

Li, Z., Nagy, A., Lindner, D., Duff, K., Garcia, E., Ay, H., Rondón, J. C., & Yel, L. (2024) · Journal of Clinical Immunology · doi:10.1007/s10875-024-01742-5 · Cited by 4 · see citing works

PHARMACEUTICAL AND CLINICAL CHALLENGES OF BIOLOGICAL MEDICINES: ONGOING HURDLES FROM DRUG DEVELOPMENT TO THERAPEUTIC APPLICATIONS

PAUL, S., & SARKAR, A. (2024) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2024v17i8.51398 · Cited by 4 · see citing works

Immunoglobulin Replacement Therapy: Insights into Multiple Myeloma Management

Saltarella, I., Altamura, C., Solimando, A. G., D’Amore, S., Ria, R., Vacca, A., Desaphy, J., & Frassanito, M. A. (2024) · Cancers · doi:10.3390/cancers16183190 · Cited by 4 · see citing works

Innovative insights on cleavage and hydrolysis mechanisms of hyaluronic acid: Opportunities and challenges in the preparation and application of hyaluronic acid and hyaluronidases

Yuan, P., Li, H., Zhu, L., Song, Z., Pan, Z., & Chen, X. (2025) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2025.101028 · Cited by 3 · see citing works

Facilitated Subcutaneous Immunoglobulin 10% Safety Among Pediatric Patients With Primary Immunodeficiency Diseases

Patel, N., & Walter, J. E. (2025) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2025.05.059 · Cited by 3 · see citing works

A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults

Nagy, A., Duff, K., Bauer, A., Okonneh, F., Rondón, J. C., Yel, L., & Li, Z. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01632-2 · Cited by 3 · see citing works

Facilitated Subcutaneous Immunoglobulin Treatment Patterns in Pediatric Patients with Primary Immunodeficiency Diseases

Mach-Tomalska, M., Pituch‐Noworolska, A., Bień, E., Malanowska, M., Machura, E., Pukas-Bochenek, A., Chrobak, E., Pac, M., Pietrucha, B. M., Drygała, S., et al. (2024) · Immunotherapy · doi:10.2217/imt-2023-0305 · Cited by 3 · see citing works

Comparison of Post-Vaccination Cellular Immune Response in Patients with Common Variable Immune Deficiency

Kostinova, A. M., Latysheva, E. A., Костинов, М. П., Ахматова, Н. К., Skhodova, S. A., Vlasenko, A. E., Cherdantsev, A. P., Soloveva, I. L., Khrapunova, I. A., Локтионова, М. Н., et al. (2024) · Vaccines · doi:10.3390/vaccines12080843 · Cited by 2 · see citing works

Pharmacokinetics, safety, and efficacy of 20% subcutaneous immunoglobulin (Ig20Gly) administered weekly or every 2 weeks in Japanese patients with primary immunodeficiency diseases: a phase 3, open-label study

Kanegane, H., Endo, A., Okada, S., Ohnishi, H., Ishimura, M., Nishikomori, R., Imai, K., Nonoyama, S., Muramatsu, H., Wada, T., et al. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltae001 · Cited by 2 · see citing works

fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study

Čižnár, P., Roderick, M. R., Schneiderová, H., Jeseňák, M., Kriván, G., Brodszki, N., Jolles, S. R. A., Atisso, C. M., Fielhauer, K., Saeed-Khawaja, S., et al. (2024) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-024-00904-9 · Cited by 2 · see citing works

Feasibility and resource utilization of nurse-administered subcutaneous immunoglobulin therapy in antibody deficiency: A cross-sectional study

Ghia, D., Thota, P., Ritchie, T., Rana, H., Minhas, R., Moolji, J., Ritchie, B. C., & Adatia, A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316797 · Cited by 2 · see citing works

Hyaluronidase-Facilitated High-Dose Subcutaneous IgG Effectively Controls Parvovirus B19 Infection in a Pediatric Cardiac Transplant Patient With Severe T-Cell Lymphopenia

Cruz, R. J., Dasso, J. F., Duff, C. M., Krasnopero, D., Long, Z. B., Ellison, M., Nieves, D., Sriaroon, P., Asante‐Korang, A., & Walter, J. E. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa076 · Cited by 2 · see citing works

The promising expedition of the delivery systems for monoclonal antibodies

Megahed, M. A., El‐Sawy, H. S., & El‐Say, K. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819666-3.00003-1 · Cited by 2 · see citing works

Treatment of primary immunodeficiencies and inborn errors of immunity

Kobrynski, L. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95061-9.00048-5 · Cited by 1 · see citing works

Infusion parameters, safety, and practical guidance for the manual administration of subcutaneous immunoglobulin 20% (Ig20Gly)

Grosse‐Kreul, D., Allen, C., Kalicinsky, C., & Keith, P. K. (2024) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-024-00914-7 · Cited by 1 · see citing works

Healthcare resource utilization and costs in immunodeficient patients receiving subcutaneous Ig: Real-world evidence from France

Lefèvre, G., Borget, I., Lefèvre, C., Maherzi-Mechalikh, C., Nucit, A., Hennaoui, M., Schmidt, A., Lennon, H., Grenier, B., Daydé, F., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0313694 · Cited by 1 · see citing works

The economic value of self-administered subcutaneous immunoglobulin G (SCIg) in Canada: a scoping review

Cheung, A., Manuel, M., Mac, S., Fakhraei, R., Giangregorio, A., & Betschel, S. (2026) · Journal of Medical Economics · doi:10.1080/13696998.2026.2628450 · Cited by 1 · see citing works

Pharmacokinetic modeling and quantitative prediction of subcutaneous absorption of antibody-based therapeutics – An update

Siemiątkowska, A., Park, C., & Kagan, L. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115916 · Cited by 1 · see citing works

Management of Humoral Primary Immunodeficiencies in Pediatrics

Azzari, C., & Canessa, C. (2018) · Rare diseases of the immune system · doi:10.1007/978-3-319-91785-6_20 · Cited by 1 · see citing works

The Experiences of Children with Primary Immunodeficiency Who Receive Immunoglobulin Subcutaneously Instead of Intravenously

Köse, S., Sabetsarvestani, R., Geçkil, E., Kaleci, E., & DÖNMEZ, H. (2023) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2023.08.002 · Cited by 1 · see citing works

Expression of Toll-like Receptors on the Immune Cells in Patients with Common Variable Immune Deficiency after Different Schemes of Influenza Vaccination

Kostinova, A. M., Latysheva, E. A., Ахматова, Н. К., Vlasenko, A. E., Skhodova, S. A., Khromova, E. A., Linok, A. V., Poddubikov, A. A., Latysheva, T. V., & Костинов, М. П. (2023) · Viruses · doi:10.3390/v15102091 · Cited by 1 · see citing works

Process Development of Protein Therapeutics

Thomas, J. N., Guhan, S., & Pettit, D. K. (2010) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc160 · Cited by 1 · see citing works

Process Development of Protein Therapeutics

Huang, Y., Bowes, B. D., Yang, T., Thomas, J. N., Guhan, S., & Pettit, D. K. (2021) · Burger's Medicinal Chemistry and Drug Discovery · doi:10.1002/0471266949.bmc160.pub2 · Cited by 1 · see citing works

Message from the Editor: Welcome to the 10th Volume of Immunotherapy

Mannan, S. (2017) · Immunotherapy · doi:10.2217/imt-2017-0158

Enabling a flexible care setting in oncology—how to realize home- and self-administration of biotherapeutics in cancer care

Bittner, B., & Schmidt, J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-823741-0.00006-3

Complications of Injectable Agents Used Intraoperatively

Szadek, K. M., Liebregts, R., Liem, A. L., & Steegers, M. A. H. (2022) · doi:10.1002/9781119757306.ch9

Intradermal Hyaluronidase: The Answer to Treatment in Softening a Fibrous Thick Supratip Skin in Rhinoplasty?

Yap, E. C., & Porquez, J. M. (2023) · Philippine Journal of Otolaryngology Head and Neck Surgery · doi:10.32412/pjohns.v38i1.2153

Additional file 2 of Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

Keith, P. K., Cowan, J., Kanani, A. S., Kim, H., Lacuesta, G., Lee, J. K., Chen, J., Park, M., & Gladiator, A. (2022) · Figshare · doi:10.6084/m9.figshare.20445926

Additional file 1 of Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

Keith, P. K., Cowan, J., Kanani, A. S., Kim, H., Lacuesta, G., Lee, J. K., Chen, J., Park, M., & Gladiator, A. (2022) · Figshare · doi:10.6084/m9.figshare.20445923

Recombinant human hyaluronidase PH20 facilitates rapid subcutaneous infusion: two randomized, double-blind, self-controlled phase III clinical trials

Ma, H., Lu, X., Xiu, J., Cao, M., Li, J., Qiao, Y., Liu, Y., Wang, Z., Zhang, L., Qian, X., et al. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115070

Pharmacokinetics of hyaluronidase-facilitated subcutaneous immunoglobulin 10% in pediatric patients with primary immunodeficiency disease

Li, Z., Teng, Y., Russo-Schwarzbaum, S., & McCoy, B. (2025) · Immunotherapy Advances · doi:10.1093/immadv/ltag003

Challenging the myths of subcutaneous delivery: An industry expert perspective

Bittner, B., Buist, N., Bruin, G. J. M., Harris, K., Huille, S., Mittal, S., Printz, M. A., Sánchez-Félix, M., Shih, H., Venczel, M., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114902

Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administered with a Prefilled Syringe

Muynck, C. D., Noukens, J., Allosery, K., Cettour-Rose, C., Pastouret, S., Andre, A. D., & Borgions, F. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03733-x

Comparison of hyaluronidase-facilitated subcutaneous immunoglobulin 10% pharmacokinetics in pediatric and adult patients with primary immunodeficiency: an analysis of three phase 3 clinical trials

Li, Z., & Ballesteros‐Perez, A. (2025) · Immunotherapy Advances · doi:10.1093/immadv/ltag022

Overview of Recombinant Human Hyaluronidase-facilitated Subcutaneous Infusion of IgG in Primary Immunodeficiencies

Wasserman, R. L. (2014) · Immunotherapy · doi:10.2217/imt.14.34 · Cited by 65 · see citing works

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency

Jolles, S. R. A. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s31136 · Cited by 28 · see citing works

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency

Wasserman, R. L., Melamed, I., Stein, M. R., Gupta, S., Puck, J. M., Engl, W., Leibl, H., McCoy, B., Empson, V. G., Gelmont, D. M., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.06.021 · Cited by 151 · see citing works

Human Immunoglobulin 10 % with Recombinant Human Hyaluronidase: Replacement Therapy in Patients with Primary Immunodeficiency Disorders

Sanford, M. (2014) · BioDrugs · doi:10.1007/s40259-014-0104-3 · Cited by 18 · see citing works

Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency

Wasserman, R. L., Melamed, I., Stein, M. R., Engl, W., Sharkhawy, M., Leibl, H., Puck, J., Rubinstein, A., Kobrynski, L., Gupta, S., et al. (2016) · Journal of Clinical Immunology · doi:10.1007/s10875-016-0298-x · Cited by 52 · see citing works